The invention relates to an aqueous ophthalmic pharmaceutical composition comprising: a) at least 0.4% w/v of bilastine, of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein the bilastine salt or solvate thereof is completely dissolved in the pharmaceutical composition； b) at least one β-cyclodextrin； and c) at least one pharmaceutically acceptable water-soluble gelling agent； and wherein the pH is comprised between 4 and 9. and its use in the treatment and/or prevention of conditions mediated by H
